Australian-headquartered biotech Aravax, which is focused on treating food allergies with next-generation immunotherapies, has established a UK subsidiary, based at the Oxford Science Park.
The firm said the UK operations will drive the development of commercial manufacturing for the peptide drug substances underpinning Aravax’s advanced immunotherapies as its lead candidate PVX108 for peanut allergy approaches Phase 3 development.
READ MORE: Science Creates start-ups raise £33M this year to pursue deep tech ambitions
It will also provide the company with a “truly international footprint” for business development, it said.
CEO Dr Pascal Hickey said: “Our ambition is to become a global leader in food allergy therapeutics through the development of safe and convenient immunotherapies which meet the critical need for better treatments.
“We believe this requires an international mindset and capabilities and the setting up of our Oxford operations is a significant step in our development.”
Dr Paul Laidler, vice president, pharmaceutical development at the company added: “Having operations in Oxford provides the opportunity to benefit from the best in UK and European manufacturing expertise for sterile, peptide-based products, and also from the wider worldwide life sciences ecosystem.”
Aravax said it expected to invest around US$10m in manufacturing development over the next two years
Its Phase 2 clinical study on PVX108 in Australia and the USA is now fully recruited, with results expected in the first half of 2026.
This post was originally published on here
